WO2016203352A3 - Compositions et méthodes de traitement du cancer - Google Patents

Compositions et méthodes de traitement du cancer Download PDF

Info

Publication number
WO2016203352A3
WO2016203352A3 PCT/IB2016/053457 IB2016053457W WO2016203352A3 WO 2016203352 A3 WO2016203352 A3 WO 2016203352A3 IB 2016053457 W IB2016053457 W IB 2016053457W WO 2016203352 A3 WO2016203352 A3 WO 2016203352A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
formula
administration
cancer
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/053457
Other languages
English (en)
Other versions
WO2016203352A2 (fr
Inventor
Alapati MOHAN M
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2016/053291 external-priority patent/WO2016203337A2/fr
Application filed by Individual filed Critical Individual
Publication of WO2016203352A2 publication Critical patent/WO2016203352A2/fr
Publication of WO2016203352A3 publication Critical patent/WO2016203352A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions et des composés de formule I, formule II, formule III et formule IV, comprenant des conjugués moléculaires d'inhibiteur de topoisomérase ou leurs formes polymorphes, leurs énantiomères, leurs stéréoisomères, leurs solvates et leurs hydrates. Ces composés peuvent être formulés sous forme de compositions pharmaceutiques. Lesdites compositions pharmaceutiques peuvent être formulées en vue d'une administration orale, d'une libération retardée ou d'une libération prolongée, d'une administration transmucosale, sous forme de sirop, intraveineuse, topique ou parentérale, d'une injection, d'une administration sous-dermique, sous forme de solution orale ou par voie rectale, ou d'une administration sous forme de nanoparticule, par voie buccale ou transdermique. De telles compositions peuvent être utilisées pour le traitement de métastases, de néoplasmes, de carcinomes métastatiques du côlon ou du rectum, du cancer du sein métastatique, du cancer des ovaires résistant au platine, du gliome de haut grade réfractaire au bevacizumab (avastin), du cancer bronchopulmonaire "non à petites cellules", du cancer pulmonaire à petites cellules, et des tumeurs gastro-intestinales et solides.
PCT/IB2016/053457 2015-06-14 2016-06-11 Compositions et méthodes de traitement du cancer Ceased WO2016203352A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN2973/CHE/2015 2015-06-14
IN2973CH2015 2015-06-14
PCT/IB2016/053291 WO2016203337A2 (fr) 2015-06-14 2016-06-04 Compositions et méthodes de traitement du cancer
IN201641019318 2016-06-04
IBPCT/IB2016/053291 2016-06-04
IN201641019318 2016-06-04
IN201641019751 2016-06-08
IN201641019751 2016-06-08

Publications (2)

Publication Number Publication Date
WO2016203352A2 WO2016203352A2 (fr) 2016-12-22
WO2016203352A3 true WO2016203352A3 (fr) 2017-02-09

Family

ID=57545448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/053457 Ceased WO2016203352A2 (fr) 2015-06-14 2016-06-11 Compositions et méthodes de traitement du cancer

Country Status (1)

Country Link
WO (1) WO2016203352A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604463A (en) * 1983-07-14 1986-08-05 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP2269580A2 (fr) * 2004-09-07 2011-01-05 Biocompatibles UK Limited Compositions comprenant des camptothecines dans des microsphères
US20110144342A1 (en) * 2009-11-18 2011-06-16 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4- (1-piperidino)- 1-piperidino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012096832A2 (fr) * 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Dérivés de camptothécine inhibiteurs de hdac

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604463A (en) * 1983-07-14 1986-08-05 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP2269580A2 (fr) * 2004-09-07 2011-01-05 Biocompatibles UK Limited Compositions comprenant des camptothecines dans des microsphères
US20110144342A1 (en) * 2009-11-18 2011-06-16 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4- (1-piperidino)- 1-piperidino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012096832A2 (fr) * 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Dérivés de camptothécine inhibiteurs de hdac

Also Published As

Publication number Publication date
WO2016203352A2 (fr) 2016-12-22

Similar Documents

Publication Publication Date Title
CR20180579A (es) Compuestos de 1-tetrahidropiranilcarbonil-2,3-dihidro-1h-indol para el tratamiento de cáncer
WO2014201026A3 (fr) Dérivés antioxydants, anti-inflammatoires et anticancéreux du triptolide et nanosphères à base de ceux-ci
WO2013093508A3 (fr) Inhibiteurs de la voie wnt
CY1119844T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EP4234722A3 (fr) Détection de néoplasme colorectal
EP4494710A3 (fr) Composition pharmaceutique comprenant un conjugué anticorps anti-her3-médicament destiné à être utilisé dans le traitement de cancers du sein
MX381587B (es) Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos.
NZ604973A (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
PE20170384A1 (es) Compuesto piridinicos de planieolida y metodos de uso
WO2014141057A3 (fr) Compositions et méthodes de traitement du cancer
GT200500229A (es) Compuestos orgánicos
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
NZ701832A (en) Compositions and methods for treatment of inflammatory bowel disease
MX386467B (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
EA201891443A1 (ru) Фармацевтические композиции, содержащие фениламинопиримидиновое производное
RU2017107681A (ru) Производные хиназолина
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
BR112015013350A2 (pt) compostos de triazolona e usos dos mesmos
WO2014091384A3 (fr) Compositions et méthodes pour le traitement de la mucosite
EA201590315A1 (ru) Средства и способ лечения солидных опухолей
UA120083C2 (uk) АНТИМЕТАСТАТИЧНІ 2H-СЕЛЕНОФЕНО[3,2-h]ХРОМЕНИ, ЇХ СИНТЕЗ ТА СПОСОБИ ЗАСТОСУВАННЯ ЦИХ АГЕНТІВ
WO2016203352A3 (fr) Compositions et méthodes de traitement du cancer
WO2016203337A3 (fr) Compositions et méthodes de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16811106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16811106

Country of ref document: EP

Kind code of ref document: A2